Imagion Biosystems secures US$150,000 non-dilutive funding line from Executive Chairman
Imagion Biosystems (ASX: IBX) has entered into a loan agreement with its Executive Chairman, Mr. Robert Proulx, providing the clinical-stage medical imaging company with a US$150,000 non-dilutive funding line to support its working capital requirements.
The facility is structured as a drawdown-as-needed arrangement, meaning the Company can access capital only when required, with interest charged solely on funds actually drawn. This approach preserves flexibility while avoiding the immediate share issuance associated with an equity raise.
Imagion is developing clinical applications for MagSense®, an MRI imaging agent designed to support the earlier and more precise detection of cancers.
The headline terms of the loan include:
- Maximum principal: US$150,000
- Interest rate: 8.0% per annum, charged only on funds drawn
- Term: four months from advance of funds
- Security: unsecured
- Lender: Executive Chairman, Mr. Robert Proulx
When big ASX news breaks, our subscribers know first
Inside the loan terms
The Company can draw down under the agreement as and when required, rather than receiving the full principal upfront. Interest accrues only on amounts actually advanced, and any advance is repayable within four months of that advance.
The agreement also contains conversion rights. Subject to certain terms and conditions, outstanding amounts advanced under the agreement (including, where applicable, accrued interest) may be converted into fully paid ordinary shares in the Company.
Any such conversion would be undertaken in accordance with the ASX Listing Rules and is subject to the satisfaction of relevant conditions and any required shareholder or regulatory approvals. The announcement does not disclose a conversion price or number of shares.
An Appendix 3B has been lodged concurrently, reflecting the maximum number of securities that may be issued under the conversion mechanism described in the agreement.
| Term | Detail |
|---|---|
| Maximum Principal | US$150,000 |
| Interest Rate | 8.0% p.a. (on drawn funds only) |
| Term | 4 months from advance |
| Security | Unsecured |
| Repayment | Within 4 months of any advance |
| Conversion | Optional, subject to conditions & approvals |
Why a related-party loan on arm’s length terms matters
Because the lender is the Company’s Executive Chairman, the transaction is a related-party dealing. The Board, with the Executive Chairman abstaining from all deliberations and decisions regarding the transaction, considers that the loan has been entered into on arm’s length commercial terms.
The Company believes the financing provides an efficient source of funding and is in the best interests of the Company and all shareholders.
For shareholders, the non-dilutive structure is the key distinction. Unlike a straight equity raise, the loan does not issue new shares at the outset, giving the Company flexible working capital without immediately diluting existing holdings.
What “non-dilutive funding” means for shareholders
Non-dilutive funding refers to raising capital through debt, such as a loan, rather than by issuing new shares. Because no new shares are created upfront, existing shareholders’ proportional ownership is not immediately reduced, unlike a placement or rights issue.
The conversion feature adds a conditional dimension. The loan could later convert into shares, but only if the relevant conditions are met and any required approvals are obtained. Any potential dilution is therefore conditional and future-dated, not immediate.
For a clinical-stage company, this flexibility carries particular weight. Such businesses are typically pre-revenue and rely on external funding to advance their programmes, so a drawn-as-needed facility can help manage cash burn more efficiently.
What happens next
The Company has stated it will make further announcements as appropriate, including if and when any conversion occurs. The concurrently lodged Appendix 3B relates to the potential issue of shares should the relevant conditions be satisfied.
Proceeds from the facility support working capital as Imagion advances MagSense® clinical applications across HER2+ breast, prostate and ovarian cancers.
FDA clearance for MagSense arrived in June 2026, with the agency issuing a Study May Proceed Notice and assigning IND number 165081, converting the regulatory milestone directly into a pathway for patient recruitment across multiple US clinical sites in Q3 2026.
For investors, the arrangement represents a modest, flexible and non-dilutive facility that supports near-term operations while Imagion continues to advance its cancer-detection pipeline.
Investors exploring the commercial and clinical context behind Imagion’s funding activity will find our deep-dive into the MagSense platform and cancer diagnostics market covers the Phase 1 trial results, addressable market sizing across three cancer indications, and the company’s financial position heading into Phase 2, all in one place.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare and biotech news to your inbox within minutes of release, complete with in-depth analysis so the work is already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button to start receiving alerts today.